Prognostic value of FDG-PET in Hodgkin lymphoma for posttreatment evaluation. Long term follow-up results.

被引:10
|
作者
Molnar, Z. [1 ]
Simon, Z. [2 ]
Borbenyi, Z. [4 ,5 ]
Deak, B. [1 ]
Galuska, L. [3 ]
Keresztes, K. [2 ]
Miltenyi, Z. [2 ]
Marton, I. [4 ,5 ]
Rosta, A. [1 ]
Schneider, T. [1 ]
Tron, L. [3 ]
Varady, E. [1 ]
Illes, A. [2 ]
机构
[1] Natl Inst Oncol, Budapest, Hungary
[2] Univ Debrecen, Inst Internal Med, Dept 3, Debrecen, Hungary
[3] Univ Debrecen, PET Ctr, Med & Hlth Sci Ctr, Debrecen, Hungary
[4] Univ Szeged, Fac Med, Dept Med 2, Szeged, Hungary
[5] Univ Szeged, Fac Med, Ctr Cardiol, Szeged, Hungary
关键词
FDG-PET; Hodgkin lymphoma; prognosis; long-term follow up; POSITRON-EMISSION-TOMOGRAPHY; MALIGNANT-LYMPHOMA; RESIDUAL MASS; DISEASE; THERAPY; F-18-FLUORODEOXYGLUCOSE; CLASSIFICATION;
D O I
10.4149/neo_2010_04_349
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Determining the viability of residual tumor masses is a great challenge after primary treatment of Hodgkin lymphoma. FDG-PET may play a crucial role in this procedure. In this study, files of 128 Hodgkin lymphoma patients were reviewed, who were treated in three Hungarian hematology centers between January 1995 and February 2005. CT scan showed residual tumor mass by all of them. Their median follow-up was 75.5 months from PET examination. The number of true-positive, true-negative, false-positive, false-negative subjects were 29, 83, 10, 6, respectively. Sensitivity of post-treatment FDG-PET was 83 %, specificity 93 %, positive predictive value 74 %, negative predictive value 93 To, and accuracy 88 %. The difference between the event free survival of PET positive and negative cases is highly significant (p=0.0000), according to the Mantel-Cox test. Our results in the largest cohort of patients, in accordance with literature, clearly indicates that patients with negative FDG-PET results are unlikely to progress or relapse during the longest follow-up.
引用
收藏
页码:349 / 354
页数:6
相关论文
共 50 条
  • [1] Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis
    Adams, Hugo J. A.
    Nievelstein, Rutger A. J.
    Kwee, Thomas C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (03) : 356 - 366
  • [2] Controversies on the prognostic value of interim FDG-PET in advanced-stage Hodgkin lymphoma
    Adams, Hugo J. A.
    Kwee, Thomas C.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 97 (06) : 491 - 498
  • [3] Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma
    Rhodes, Melissa M.
    Delbeke, Dominique
    Whitlock, James A.
    Martin, William
    Kuttesch, John F.
    Frangoul, Haydar A.
    Shankar, Sadhna
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2006, 28 (05) : 300 - 306
  • [4] Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma
    Hutchings, M
    Mikhaeel, NG
    Fields, PA
    Nunan, T
    Timothy, AR
    ANNALS OF ONCOLOGY, 2005, 16 (07) : 1160 - 1168
  • [5] FDG-PET for the early treatment monitoring, for final response and follow-up evaluation in lymphoma
    Hutchings M.
    Barrington S.
    Clinical and Translational Imaging, 2015, 3 (4) : 271 - 281
  • [6] Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin's lymphoma
    Crocchiolo, R.
    Fallanca, F.
    Giovacchini, G.
    Ferreri, A. J. M.
    Assanelli, A.
    Verona, C.
    Pescarollo, A.
    Bregni, M.
    Ponzoni, M.
    Gianolli, L.
    Fazio, F.
    Ciceri, F.
    ANNALS OF HEMATOLOGY, 2009, 88 (12) : 1229 - 1236
  • [7] Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma
    Adams, Hugo J. A.
    Kwee, Thomas C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (11) : 1934 - 1936
  • [8] The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood
    Sioka, Chrissa
    EUROPEAN JOURNAL OF PEDIATRICS, 2013, 172 (06) : 733 - 738
  • [9] Prognostic value of interim and restaging PET/CT in Hodgkin lymphoma. Results of the CHEAP (Chemotherapy Effectiveness Assessment by PET/CT) study - long term observation
    Miltenyi, Z.
    Barna, S.
    Garai, I.
    Simon, Z.
    Jona, A.
    Magyari, F.
    Gergely, M.
    Nagy, Z.
    Keresztes, K.
    Pettendi, P.
    Illes, A.
    NEOPLASMA, 2015, 62 (04) : 627 - 634
  • [10] FDG PET/CT of Metabolic Myopathy With Posttreatment Follow-up
    McNamee, Anitia
    Robertson, Thomas
    Sounness, Brett
    O'Gorman, Patricia
    CLINICAL NUCLEAR MEDICINE, 2018, 43 (09) : E316 - E318